Nancy B. Amaro-Mugridge

1.5k total citations
16 papers, 1.2k citations indexed

About

Nancy B. Amaro-Mugridge is a scholar working on Molecular Biology, Cancer Research and Biotechnology. According to data from OpenAlex, Nancy B. Amaro-Mugridge has authored 16 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 5 papers in Cancer Research and 4 papers in Biotechnology. Recurrent topics in Nancy B. Amaro-Mugridge's work include Cancer Research and Treatments (4 papers), MicroRNA in disease regulation (4 papers) and Toxoplasma gondii Research Studies (3 papers). Nancy B. Amaro-Mugridge is often cited by papers focused on Cancer Research and Treatments (4 papers), MicroRNA in disease regulation (4 papers) and Toxoplasma gondii Research Studies (3 papers). Nancy B. Amaro-Mugridge collaborates with scholars based in Australia, United States and Germany. Nancy B. Amaro-Mugridge's co-authors include Himanshu Brahmbhatt, Jennifer A. MacDiarmid, Jocelyn Weiss, David A. Morrison, Alan M. Johnson, A.M. Tenter, Leo Phillips, Scott Pattison, Bruce Stillman and Robert M. Graham and has published in prestigious journals such as Nature Biotechnology, PLoS ONE and Cancer Cell.

In The Last Decade

Nancy B. Amaro-Mugridge

16 papers receiving 1.2k citations

Peers

Countries citing papers authored by Nancy B. Amaro-Mugridge

Since Specialization

Citations

This map shows the geographic impact of Nancy B. Amaro-Mugridge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nancy B. Amaro-Mugridge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nancy B. Amaro-Mugridge more than expected).

Fields of papers citing papers by Nancy B. Amaro-Mugridge

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nancy B. Amaro-Mugridge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nancy B. Amaro-Mugridge. The network helps show where Nancy B. Amaro-Mugridge may publish in the future.

Co-authorship network of co-authors of Nancy B. Amaro-Mugridge

This figure shows the co-authorship network connecting the top 25 collaborators of Nancy B. Amaro-Mugridge. A scholar is included among the top collaborators of Nancy B. Amaro-Mugridge based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nancy B. Amaro-Mugridge. Nancy B. Amaro-Mugridge is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Therapeutic potential of synthetic microRNA mimics based on the miR-15/107 consensus sequence 2025 ·Cancer Gene Therapy ·Glen Reid, Marissa Williams, Yuen Yee Cheng, (unknown), (unknown), Michaela B. Kirschner, Nancy B. Amaro-Mugridge, Jocelyn Weiss, Mark P. Molloy, Himanshu Brahmbhatt, Jennifer A. MacDiarmid, Nico van Zandwijk	2
2	Phase I/IIa Trial in Advanced Pancreatic Ductal Adenocarcinoma Treated with Cytotoxic Drug-Packaged, EGFR-Targeted Nanocells and Glycolipid-Packaged Nanocells 2023 ·Clinical Cancer Research ·Vinod Ganju, Gavin Marx, Scott Pattison, Nancy B. Amaro-Mugridge, Jing Zhao, Bryan R.G. Williams, Jennifer A. MacDiarmid, Himanshu Brahmbhatt	6
3	Nanocell COVID-19 vaccine triggers a novel immune response pathway producing high-affinity antibodies which neutralize all variants of concern 2023 ·Frontiers in Immunology ·(unknown), Nancy B. Amaro-Mugridge, (unknown), (unknown), Natasha Vanegas, Kumar Visvanathan, Bryan R.G. Williams, Jennifer A. MacDiarmid, Himanshu Brahmbhatt	5
4	Nanocell-mediated delivery of miR-34a counteracts temozolomide resistance in glioblastoma 2021 ·Molecular Medicine ·(unknown), Rosamaria Ruggieri, (unknown), Nhan L. Tran, Camila González, Nancy B. Amaro-Mugridge, (unknown), Jennifer A. MacDiarmid, Himanshu Brahmbhatt, Jann N. Sarkaria, John A. Boockvar, Marc Symons	18
5	Translational applications of microRNAs in cancer, and therapeutic implications 2017 ·Non-coding RNA Research ·(unknown), Jing Zhao, Jocelyn Weiss, Nancy B. Amaro-Mugridge, Himanshu Brahmbhatt, Jennifer A. MacDiarmid, Bruce G. Robinson, Stan B. Sidhu	35
6	Targeted Doxorubicin Delivery to Brain Tumors via Minicells: Proof of Principle Using Dogs with Spontaneously Occurring Tumors as a Model 2016 ·PLoS ONE ·Jennifer A. MacDiarmid, (unknown), Dale L. Bailey, Scott Pattison, (unknown), Neil Christensen, (unknown), (unknown), Katarzyna Smolarczyk, Matthew Tom Harrison, (unknown), Nancy B. Amaro-Mugridge, Ilya Sedliarou, (unknown), (unknown), Bruce Stillman, Christine L. Hann, Gary L. Gallia, Robert M. Graham, Himanshu Brahmbhatt	67
7	miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma 2015 ·Oncotarget ·Marissa Williams, Michaela B. Kirschner, Yuen Yee Cheng, (unknown), Jocelyn Weiss, Nancy B. Amaro-Mugridge, Casey M. Wright, Anthony Linton, Steven Kao, J. James Edelman, Michael P. Vallely, Brian C. McCaughan, Wendy A. Cooper, Sonja Klebe, Ruby C.Y. Lin, Himanshu Brahmbhatt, Jennifer A. MacDiarmid, Nico van Zandwijk, Glen Reid	64
8	microRNA-7 as a tumor suppressor and novel therapeutic for adrenocortical carcinoma 2015 ·Oncotarget ·Anthony Glover, Jing Zhao, Anthony J. Gill, Jocelyn Weiss, Nancy B. Amaro-Mugridge, Edward Kim, (unknown), Julian Ip, Glen Reid, Stephen Clarke, Patsy Soon, Bruce G. Robinson, Himanshu Brahmbhatt, Jennifer A. MacDiarmid, Stan B. Sidhu	74
9	Abstract 3976: Targeted delivery of a synthetic microRNA-based mimic as an approach to cancer therapy 2015 ·Cancer Research ·Glen Reid, Marissa Williams, Michaela B. Kirschner, Nancy B. Amaro-Mugridge, Jocelyn Weiss, Himanshu Brahmbhatt, Jennifer A. MacDiarmid, Nico van Zandwijk	14
10	Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma 2013 ·Annals of Oncology ·Glen Reid, (unknown), Michaela B. Kirschner, Yuen Yee Cheng, Nancy B. Amaro-Mugridge, Jocelyn Weiss, Marissa Williams, Casey M. Wright, J. James Edelman, Michael P. Vallely, Brian C. McCaughan, Sonja Klebe, Himanshu Brahmbhatt, Jennifer A. MacDiarmid, Nico van Zandwijk	202
11	Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug 2009 ·Nature Biotechnology ·Jennifer A. MacDiarmid, Nancy B. Amaro-Mugridge, (unknown), Ilya Sedliarou, Stefanie Wetzel, (unknown), (unknown), Leo Phillips, Scott Pattison, Carlotta Petti, Bruce Stillman, Robert M. Graham, Himanshu Brahmbhatt	209
12	Bacterially Derived 400 nm Particles for Encapsulation and Cancer Cell Targeting of Chemotherapeutics 2007 ·Cancer Cell ·Jennifer A. MacDiarmid, Nancy B. Amaro-Mugridge, Jocelyn Weiss, Leo Phillips, (unknown), (unknown), (unknown), Kristie-Ann Dickson, (unknown), Scott Pattison, Alexander C. James, (unknown), Rodney C. Straw, Bruce Stillman, Robert M. Graham, Himanshu Brahmbhatt	236
13	Bacterially-Derived Nanocells for Tumor-Targeted Delivery of Chemotherapeutics and Cell Cycle Inhibitors 2007 ·Cell Cycle ·Jennifer A. MacDiarmid, (unknown), Nancy B. Amaro-Mugridge, Leo Phillips, Himanshu Brahmbhatt	28
14	Effects of Sequence Alignment and Structural Domains of Ribosomal DNA on Phylogeny Reconstruction for the Protozoan Family Sarcocystidae 2000 ·Molecular Biology and Evolution ·Nancy B. Amaro-Mugridge, David A. Morrison, Thomas Jäkel, Anja R. Heckeroth, A.M. Tenter, Alan M. Johnson	92
15	Phylogenetic relationships of the genus Frenkelia : a review of its history and new knowledge gained from comparison of large subunit ribosomal ribonucleic acid gene sequences 1Note: Nucleotide sequence data reported in this paper are available in the EMBL, GenBank™, and DDJB databases under the accession numbers U85705-6, AF012883, AF092927, and AF044250-2. 1 1999 ·International Journal for Parasitology ·Nancy B. Amaro-Mugridge, David A. Morrison, Alan M. Johnson, Kim Luton, J. P. Dubey, Jan Votýpka, A.M. Tenter	70
16	Phylogenetic analysis based on full-length large subunit ribosomal RNA gene sequence comparison reveals that Neospora caninum is more closely related to Hammondia heydorni than to Toxoplasma gondii1Note: Nucleotide sequence data reported in this paper are available in the EMBL, GenBank™ and DDJB databases under the accession numbers AF159240 (Hammondia heydorni), AF101077 (Hammondia hammondi), AF076899 (Sarcocystis tenella) and AF076901 (Toxoplasma gondii ME49 strain).1 1999 ·International Journal for Parasitology ·Nancy B. Amaro-Mugridge, David A. Morrison, Anja R. Heckeroth, Alan M. Johnson, A.M. Tenter	82

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact